Ropsacitinib

Last updated

Ropsacitinib
Ropsacitinib structure.png
Identifiers
  • 3-(cyanomethyl)-3-[4-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]pyrazol-1-yl]cyclobutane-1-carbonitrile
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEMBL
Chemical and physical data
Formula C20H17N9
Molar mass 383.419 g·mol−1
3D model (JSmol)
  • CN1C=C(C=N1)C2=CN3C(=CC=N3)C(=N2)C4=CN(N=C4)C5(CC(C5)C#N)CC#N
  • InChI=1S/C20H17N9/c1-27-11-15(9-24-27)17-13-28-18(2-5-23-28)19(26-17)16-10-25-29(12-16)20(3-4-21)6-14(7-20)8-22/h2,5,9-14H,3,6-7H2,1H3
  • Key:XPLZTJWZDBFWDE-UHFFFAOYSA-N

Ropsacitinib (PF-06826647) is a drug which is an orally active, selective tyrosine kinase 2 (TYK2) inhibitor. It has been researched for various autoimmune inflammatory conditions, primarily plaque psoriasis. [1] [2] [3]

See also

References

  1. ↑ Martin G (February 2023). "Novel Therapies in Plaque Psoriasis: A Review of Tyrosine Kinase 2 Inhibitors". Dermatology and Therapy. 13 (2): 417–435. doi:10.1007/s13555-022-00878-9. PMC   9884727 . PMID   36592300.
  2. ↑ Zhang K, Ye K, Tang H, Qi Z, Wang T, Mao J, et al. (April 2023). "Development and Therapeutic Implications of Tyrosine Kinase 2 Inhibitors". Journal of Medicinal Chemistry. 66 (7): 4378–4416. doi:10.1021/acs.jmedchem.2c01800. PMID   36951608.
  3. ↑ Morand E, Merola JF, Tanaka Y, Gladman D, Fleischmann R (April 2024). "TYK2: an emerging therapeutic target in rheumatic disease". Nature Reviews. Rheumatology. 20 (4): 232–240. doi:10.1038/s41584-024-01093-w. PMID   38467779.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.